10/20/2023 0 Comments Choudhry lawrence township nj![]() ![]() The easiest way to travel here is along the Northeast Corridor line. Train stop: Hamilton Station (2.67 mi away). Merely a 1 minute trip from Town Court North, Palm Street, Exit 67A-B of I-295 and Cedar Court a 4 minute drive from Village Road West, Lawrence Station Road or Brunswick Pike and a 11 minute trip from Princeton Pike or Province Line Road.įor those using GPS navigator systems to get to this location, enter this address: 4100 Quakerbridge Road, Lawrence Township, NJ 08648. Nivolumab is likely to be cost-effective for the treatment of patients with advanced NSCLC following platinum-based chemotherapy in the United States.Getting Here - Quakerbridge Road, Lawrence TownshipĬostco can be found in a good location near the intersection of Quakerbridge Road and Avalon Way, in Lawrence Township, New Jersey. ![]() At a willingness-to-pay threshold of $150,000, nivolumab had probabilities of 91% and 99% of being cost-effective in patients with squamous and nonsquamous NSCLC, respectively. ICERs were most sensitive to the discount rates applied to costs and outcomes. Costs were increased by $94,174, resulting in ICERs of $117,739 per QALY and $94,849 per LYG. In patients with nonsquamous NSCLC, nivolumab increased LYs and QALYs by 0.99 and 0.80, respectively. Costs were increased by $99,677, resulting in ICERs of $100,776 per QALY and $81,294 per LYG. In patients with squamous NSCLC, the use of nivolumab improved life-years (LYs) and QALYs by 1.23 and 0.99, respectively, compared with docetaxel. Uncertainty was examined using univariate and probabilistic sensitivity analyses. Costs and outcomes were discounted at 3% per annum. ![]() The primary outcomes were quality-adjusted life-years (QALYs), life-years gained (LYG), and incremental cost-effectiveness ratios (ICERs). Costs were derived from published literature. Clinical parameters were derived from the 2 registrational, randomized, phase 3 trials with a minimum follow-up of 5 years. The analyses used partitioned survival models with 3 mutually exclusive health states: progression free, progressed disease, and death. Trial- and cohort-based cost-effectiveness analyses. ![]() To determine the lifetime cost-effectiveness of nivolumab vs docetaxel in advanced squamous and nonsquamous non-small cell lung cancer (NSCLC) following platinum-based chemotherapy from a US payer perspective. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |